#### THE EFFICACY OF CARIPRAZINE IN LIGHT OF ITS RECEPTOR PROFILE

#### G. Vass<sup>a</sup>, B. Sebe<sup>a</sup>, A. Barabassy<sup>a</sup>, Zs. Dombi<sup>a</sup>, I. Laszlovszky<sup>a</sup>, B. Szatmari<sup>a</sup>, K. Acsai<sup>a</sup>, B. Kiss<sup>b</sup>, M. Patel<sup>c</sup>, W. Earley<sup>d</sup>, O. Lam<sup>e</sup>, G. Németh<sup>a</sup>

<sup>a</sup>Gedeon Richter Plc., Medical Division, Budapest, Hungary; <sup>b</sup>Gedeon Richter Plc., Pharmacology Department, Budapest, Hungary; <sup>c</sup>AbbVie Plc., Medical Department, Madison- NJ, USA; <sup>d</sup>AbbVie Plc., Clinical Department, Madison- NJ, USA; <sup>e</sup>Mitsubishi Tanabe Pharma Singapore Pte. Ltd., Singapore

### INTRODUCTION

complex neurochemical The dysfunction of schizophrenia manifests in positive, negative, cognitive and affective symptoms. Optimal treatment requires not only the management of positive symptoms but favourable effects in all these dimensions.<sup>1</sup> Cariprazine is a partial agonist antipsychotic, approved for schizophrenia and symptoms of bipolar disorder I.<sup>2,3</sup> Cariprazine's broad therapeutic effect is mediated by its partial agonist activity at dopamine D3/D2/5-HT2B receptors.<sup>4</sup>

### **STUDY OBJECTIVES**

This poster's objective is to present the efficacy of cariprazine in schizophrenia in light of its receptor profile.

## **METHODS**

The *in vitro* receptor binding profile of cariprazine was characterized. Data from five Phase 3, efficacy studies (NCT00694707, NCT01104766, NCT01104779, EudraCT2012-005485-36, NCT01412060) in patients with schizophrenia were analyzed.

## RESULTS

Table 1 Efficacy measures

**Negative symptoms** vs risperidone

Cognitive symptoms vs risperidone

Positive symptoms vs placebo

Affective symptoms vs placebo

Relapse prevention vs placebo

(PANSS, Marder Negative Symptom Factor)

(PANSS, Marder Positive Symptom Factor)

(PANSS, Marder Anxiety/Depression Factor)

(PANSS, Marder Disorganized Thought Factor)

Efficacy measures

**PNS** population

Acute population

Stable patients

(Relapse rate)

Cariprazine has the highest affinity to D3 receptors (Ki 0.085-0.3nM), reflecting strong efficacy against negative cognitive symptoms versus risperidone in a predominantly negative symptom (PNS) population. Its D2 activity (Ki 0.49-0.71nM) translates into strong efficacy against positive symptoms and relapse prevention as demonstrated in acute and stable patients. Its affinity to 5-HT1A (Ki 1.4-2.6nM), 5-HT2B (Ki 0.58-1.1nM) and 5-HT2A (Ki 18.8nM) receptors may be responsible for its effects on affective symptoms.

p=0.0022

p=0.05


p<0.0001

p<0.0015

0.45

Hazard Ratio=

#### Figure 1. Cariprazine's in vitro receptor affinities (Ki values, nM)



# CONCLUSION

Potentially related

receptors

D2, 5-HT2B

HT2A

D2

5-HT1A, 5-HT2B, 5-

D3

Due to its unique receptor profile, cariprazine is an effective
antipsychotic for broad symptoms of schizophrenia.

# REFERENCES

Lehman AF, Lieberman JA, Dixon LB, et al. Am J Published Psvchiatrv. online 2004. doi:10.1176/appi.books.9780890423363.45859 2. Fagiolini A, Alcalá JÁ, Aubel T, et al. Ann Gen Psychiatry. Published online 2020. doi:10.1186/s12991-020-00305-3 3. Stahl SM, Laredo S. Morrissette DA. Ther Adv *Psychopharmacol.* Published online 2020. doi:10.1177/2045125320905752 4.Kiss B, Horvath A, Nemethy Z, et al. J Pharmacol Exp Ther. 2010;333(1):328-340. doi:10.1124/jpet.109.160432

# DISCLOSURE

Studies were funded by Gedeon Richter Plc. and Allergan Plc. (prior to its acquisition by AbbVie). Dr. Vass, Dr. Sebe, Dr. Barabassy, Ms Dombi, Dr. Laszlovszky, Dr. Szatmári, Mr. Acsai, Mr. Kiss, and Dr Németh are employees of Gedeon Richter Plc., Dr.

Earley and Mr. Lam are employees of AbbVie and Mitsubishi Tanabe. Dr Patel is a former employee of AbbVie.



(95% CI:0.28, 0.73)

LSMD -1.46

LSMD -0.63

LSMD -2.23

LSMD -0.60

(95% CI:-2.39, -0.53)

(95% CI:-1.26, 0.0)

(95% CI: 3.00,-1.45)

(95% CI:-0.97, -0.23);

CAR=24.8%, PBO=47.5%,